导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.32% | 1407/4773 |
| 近一周 | -1.96% | 966/5462 |
| 近一月 | 1.09% | 439/5421 |
| 近一季 | 0.95% | 602/5209 |
| 近半年 | -4.13% | 2438/4920 |
| 近一年 | 3.54% | 1912/4366 |
| 近两年 | 24.83% | 2509/2954 |
| 近三年 | 17.20% | 1576/2253 |
| 成立以来 | 73.04% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.86% 642/4961 |
-10.31% 4086/5312 |
- - |
- - |
| 2025 | 2.52% 3181/4813 |
-2.87% 2999/3635 |
2.22% 1742/4076 |
2.33% 3808/4524 |
0.91% 1674/4813 |
| 2024 | 16.21% 834/3463 |
7.69% 232/2808 |
1.83% 439/3014 |
8.11% 2772/3129 |
-1.98% 1911/3463 |
| 2023 | 4.14% 241/2656 |
4.48% 941/2280 |
0.59% 305/2385 |
3.72% 172/2515 |
-4.46% 1041/2655 |
| 2022 | -2.37% 56/2207 |
1.40% 104/1919 |
-1.19% 1687/2016 |
-2.37% 36/2113 |
-0.19% 1573/2208 |
| 2021 | 17.04% 249/1822 |
4.90% 130/1255 |
8.51% 617/1330 |
3.92% 392/1466 |
-1.06% 1305/1822 |
| 2020 | 8.70% 855/1250 |
-10.18% 764/1028 |
5.34% 884/1067 |
9.76% 627/1164 |
4.67% 831/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.17% 741/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 大成中证红利指数C VS. 长安沪深300非周期A(740101) |